Abstract:Introduction: Combining two mechanisms (GLP-1 and FGF21) can deliver synergistic and complementary functions. ZT003 is a novel long-acting GLP-1/FGF21 dual agonist, and in this study, its therapeutic potential has been explored in animal models. Methods: In vitro GLP-1 and FGF21 activities of the fusion protein were measured using a BHK cell line overexpressing human GLP-1 receptor and a HEK293 cell line overexpressing human beta-Klotho. In vivo tests were carried out in DIO mice, db/db mice and NASH mice to demonstrate the pharmacological efficacy of ZT003 on body weight, food intake, plasma glucose, circulating lipids, liver fat content, NAS score and other metabolic parameters as compared to the benchmark molecules. The pharmacokinetic parameters were measured in non-human primates. Results: ZT003 is an engineered dual agonist fusion protein comprising GLP-1, anti-HSA nanobody (for half-life extension) and FGF21 conjugated with a small molecule to prevent C-terminal degradation. In cell-based assays, ZT003 showed an optimal GLP-1/FGF21 activity ratio. When tested in DIO obese mice and db/db diabetic mice, ZT003 demonstrated synergistic, sustained, and superior body weight reduction and glucose-lowering effect versus semaglutide, tirzepatide and YH25724. When tested in DIO NASH mice, ZT003 significantly improved lipid metabolism, hepatic steatosis, and liver histology, all of these effects being greater than semaglutide. The pharmacokinetic study in cynomolgus monkeys demonstrated the half-life of ZT003 is comparable to that of semaglutide, indicative that ZT003 is likely to be amenable for once-weekly dosing in humans. Conclusion: In conclusion, this novel GLP-1/FGF21 fusion protein in animals reveals therapeutically efficacious to treat obesity, diabetes, NASH and related co-morbidities, thus demonstrating the promise of the poly-pharmaceutical approach in metabolic drug discovery and development. Y. Zhang: Employee; QL Biopharmaceutical Co. Ltd. Y. Zhang: None. C. Zhao: Employee; Beijing QL Biopharmaceutical Co., Ltd. S. Lin: None. W. Guo: Employee; Beijing QL Biopharmaceutical Co., Ltd. B. Wu: Employee; Beijing QL Biopharmaceutical Co. Ltd.

Discovery of novel glucagon-like peptide 1/cholecystokinin 1 receptor dual agonists

A GLP‐1/glucagon/CCK‐2 receptors tri‐agonist provides new therapy for obesity and diabetes

Discovery of a Novel GLP-1/GIP Dual Receptor Agonist CY-5 As Long-Acting Hypoglycemic, Anti-Obesity Agent

Design of novel Xenopus GLP-1-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists

Development of a novel Fc fusion protein dual glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonists

Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor

A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis

A Novel Glucagon-Like Peptide-1/Glucagon Receptor Dual Agonist Exhibits Weight-Lowering and Diabetes-Protective Effects.

Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors

Rational design of a GLP-1/GIP/Gcg receptor triagonist to correct hyperglycemia, obesity and diabetic nephropathy in rodent animals

Antiobesity therapeutics with complementary dual-agonist activities at glucagon and glucagon-like peptide 1 receptors

A novel DPP-IV-resistant analog of glucagon-like peptide-1 (GLP-1): KGLP-1 alone or in combination with long-acting PLGA microspheres.

Preparation and Pharmaceutical Characterizations of Lipidated Dimeric Xenopus Glucagon-like Peptide-1 Conjugates.

An Oral GLP-1 and GIP Dual Receptor Agonist Improves Metabolic Disorders in High Fat-Fed Mice

Design, Synthesis, and Biological Evaluation of Novel Pan Agonists of FFA1, PPARγ and PPARδ.

Novel Glucagon- and OXM-based Peptides Acting Through Glucagon and GLP-1 Receptors with Body Weight Reduction and Anti-Diabetic Properties.

Design, Synthesis, And Biological Activity Of Novel Dicoumarol Glucagon-Like Peptide 1 Conjugates

Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges

Discovery of First-in-class Thiazole-Based Dual FFA1/PPARδ Agonists As Potential Anti-Diabetic Agents

297-OR: A Novel GLP-1/FGF21 Dual Agonist ZT003 Has Therapeutic Potential for Obesity, Diabetes, and Nonalcoholic Steatohepatitis

Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes